Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.

[1]  Xilin Zhao,et al.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Blondeau,et al.  Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.

[3]  J. Domagala,et al.  Mutant Prevention Concentration as a Measure of Fluoroquinolone Potency against Mycobacteria , 2000, Antimicrobial Agents and Chemotherapy.

[4]  B. Kreiswirth,et al.  Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates ofMycobacterium tuberculosis , 2000, Antimicrobial Agents and Chemotherapy.

[5]  K. Drlica.  The future of fluoroquinolones , 2000, Annals of medicine.

[6]  J. Rotschafer,et al.  Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model , 1994, Antimicrobial Agents and Chemotherapy.

[7]  N. Georgopapadakou,et al.  Binding of beta-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity , 1980, Antimicrobial Agents and Chemotherapy.

[8]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[9]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .